Key result
Permanent pacemaker implantation after bicaval heart transplantation was not associated with a difference in median post-HT survival compared to matched non-PPM recipients (12.8 vs 11.5 years, P=0.14).
Why the study?
Permanent pacemaker implantation after heart transplantation is common, but contemporary data regarding utilization, outcomes, and emerging pacing technologies are limited.
Does permanent pacemaker implantation affect post-heart transplantation survival in bicaval HT recipients?
Cohort (n=1,225)
No
Does permanent pacemaker implantation affect post-heart transplantation survival in bicaval HT recipients?
Absolute Event Rate: 12.8% vs 11.5%
p-value: p=0.14
Permanent pacemaker implantation after bicaval heart transplantation is infrequent (5%), primarily indicated for sinus node dysfunction, and does not adversely affect long-term post-transplant survival.
BACKGROUND: Permanent pacemaker (PPM) implantation after heart transplantation (HT) is common, but contemporary data regarding utilization, outcomes, and emerging pacing technologies are limited. METHODS: We studied PPM placement among 1225 bicaval HT recipients (28% women) treated at our institution from 2010 to 2025 and compared PPM recipients with HT patients without PPMs matched on sex, age, and transplant year. RESULTS: Median age at HT was 58 years (interquartile range, 48–65 years). Sixty-six (5%) patients received a PPM, with stable implantation rates over time. Median HT-to-PPM time was 4.3 months (interquartile range, 2 weeks to 4.8 years). The main indications were sinus node dysfunction (41 patients, 62%) or atrioventricular block (19 patients, 29%). Median post-HT survival was similar between PPM and non-PPM recipients (12.8 versus 11.5 years, P =0.14). Older organ donor age independently predicted PPM placement (odds ratio, 1.75; P =0.04). After 3.2 years of median follow-up, 1 transvenous PPM had a major complication requiring device extraction. Thirteen (20%) patients received leadless PPMs, including 3 atrial leadless PPMs and 1 dual-chamber leadless PPM. Leadless PPMs had no short-term complications over 1 year of median follow-up. CONCLUSIONS: Post-HT PPM implantation rates were low and unchanged since 2010. Most devices were implanted for sinus node dysfunction, with 44% implanted within 1 month post-HT. PPM placement was not associated with post-HT survival. Advanced organ donor age was associated with risk of PPM placement. Transvenous PPM complication rates were comparable to rates described in general populations. Leadless PPMs accounted for a substantial minority of PPM placements since their introduction in 2018, with no complications to date. Longer follow-up is needed to establish their long-term outcomes and safety in patients with HT.
No takes yet. Share an insight, caveat, or question.
Sheppard et al. (2026) conducted a cohort in Bicaval heart transplantation (n=1,225). Permanent pacemaker (PPM) vs. No PPM (matched on sex, age, and transplant year) was evaluated on Median post-HT survival (years) (p=0.14). Permanent pacemaker implantation after bicaval heart transplantation was not associated with a difference in median post-HT survival compared to matched non-PPM recipients (12.8 vs 11.5 years, P=0.14).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: